Leuko Receives $4.5 Million NIH Grant to Advance a New Field of Non-Invasive Blood Testing

BOSTON--(BUSINESS WIRE)--Jul 23, 2024--

Leuko, a medtech company pioneering the field of non-invasive blood testing, announced today that it has received a $4.5 million SBIR Phase IIB award from the National Institutes of Health (NIH) National Cancer Institute (NCI) for the continued development of PointCheck™, the first solution that enables non-invasive white blood cell monitoring.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723997436/en/

MIT spinout Leuko has developed PointCheck, a medical device that non-invasively measures white blood cells from a patient’s home. PointCheck has potential to improve clinical outcomes and reduce costly hospital admission for cancer patients in chemotherapy. Credits: Courtesy of Leuko.

White blood cell monitoring is particularly relevant for cancer patients who receive chemotherapy and other treatments, which target cancer cells but can also destroy their white blood cells, compromising their immune system. Every year, that leads tens of thousands of cancer patients to contract dangerous infections that can turn deadly if unmanaged.

Currently, the only way for doctors to monitor their patients is through blood tests, which practically limit the frequency of monitoring. Now, Leuko is developing an at-home, non-invasive monitor, PointCheck™, to give doctors a more complete view of their patients’ health remotely. Rather than drawing blood, the device uses light to look through the skin at the top of the fingernail, and advanced algorithms to analyze and detect when white blood cells reach dangerously low levels.

By removing the need for a blood sample, Leuko enables at-home, and more frequent monitoring so that patients at risk can be identified early, enabling the care team to deploy preventive treatment that can avoid infections, reduce hospital admissions by 50%, and improve clinical outcomes.

Funds from NIH will accelerate product development and generate clinical evidence to commercialize this platform technology. “At Leuko, we are committed to deliver on our vision for non-invasive blood testing, which could transform how cancer patients and other immunocompromised populations are managed,” said Carlos Castro-Gonzalez, Co-Founder and CEO at Leuko. “Thanks to this NIH grant, we will advance to the next stage of clinical development and move closer to making this technology widely available to patients.”

About Leuko

Leuko spun out from MIT and the Madrid M+Vision Consortium. Co-founded by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro, the company is developing PointCheck™, a platform technology to non-invasively measure blood parameters. For its first application, Leuko aims to improve clinical outcomes for >2 million cancer patients a year, reduce their chemotherapy-related hospital admissions by 50%, and save >$4B in healthcare cost. For more information, visit https://leuko.com/ or follow us on LinkedIn or Twitter @leuko.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240723997436/en/

CONTACT: Carlos Castro-Gonzalez

carlos@leuko.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HARDWARE HEALTH TECHNOLOGY MANUFACTURING TECHNOLOGY SMALL BUSINESS ONCOLOGY PROFESSIONAL SERVICES GENERAL HEALTH MEDICAL DEVICES SCIENCE SOFTWARE OTHER SCIENCE HEALTH ENGINEERING RESEARCH

SOURCE: Leuko

PUB: 07/23/2024 08:00 AM/DISC: 07/23/2024 08:00 AM

http://www.businesswire.com/news/home/20240723997436/en